Wearable Devices in Cardiovascular Medicine.

Wearable devices, such as smartwatches and activity trackers, are commonly used by patients in their everyday lives to manage their health and well-being. These devices collect and analyze long-term continuous data on measures of behavioral or physiologic function, which may provide clinicians with a more comprehensive view of a patients' health compared with the traditional sporadic measures captured by office visits and hospitalizations. Wearable devices have a wide range of potential clinical applications ranging from arrhythmia screening of high-risk individuals to remote management of chronic conditions such as heart failure or peripheral artery disease. As the use of wearable devices continues to grow, we must adopt a multifaceted approach with collaboration among all key stakeholders to effectively and safely integrate these technologies into routine clinical practice. In this Review, we summarize the features of wearable devices and associated machine learning techniques. We describe key research studies that illustrate the role of wearable devices in the screening and management of cardiovascular conditions and identify directions for future research. Last, we highlight the challenges that are currently hindering the widespread use of wearable devices in cardiovascular medicine and provide short- and long-term solutions to promote increased use of wearable devices in clinical care.

Real-world walking behaviors are associated with early-stage heart failure: a Project Baseline Health Study.

BACKGROUND: Data collected via wearables may complement in-clinic assessments to monitor subclinical heart failure (HF). OBJECTIVES: Evaluate the association of sensor-based digital walking measures with HF stage and characterize their correlation with in-clinic measures of physical performance, cardiac function and participant reported outcomes (PROs) in individuals with early HF. METHODS: The analyzable cohort included participants from the Project Baseline Health Study (PBHS) with HF stage 0, A, or B, or adaptive remodeling phenotype (without risk factors but with mild echocardiographic change, termed RF-/ECHO+) (based on available first-visit in-clinic test and echocardiogram results) and with sufficient sensor data. We computed daily values per participant for 18 digital walking measures, comparing HF subgroups vs stage 0 using multinomial logistic regression and characterizing associations with in-clinic measures and PROs with Spearman's correlation coefficients, adjusting all analyses for confounders. RESULTS: In the analyzable cohort (N=1265; 50.6% of the PBHS cohort), one standard deviation decreases in 17/18 walking measures were associated with greater likelihood for stage-B HF (multivariable-adjusted odds ratios [ORs] vs stage 0 ranging from 1.18-2.10), or A (ORs vs stage 0, 1.07-1.45), and lower likelihood for RF-/ECHO+ (ORs vs stage 0, 0.80-0.93). Peak 30-minute pace demonstrated the strongest associations with stage B (OR vs stage 0=2.10; 95% CI:1.74-2.53) and A (OR vs stage 0=1.43; 95% CI:1.23-1.66). Decreases in 13/18 measures were associated with greater likelihood for stage-B HF vs stage A. Strength of correlation with physical performance tests, echocardiographic cardiac-remodeling and dysfunction indices and PROs was greatest in stage B, then A, and lowest for 0. CONCLUSIONS: Digital measures of walking captured by wearable sensors could complement clinic-based testing to identify and monitor pre-symptomatic HF.

A Systematic Review of Time Series Classification Techniques Used in Biomedical Applications.

Background: Digital clinical measures collected via various digital sensing technologies such as smartphones, smartwatches, wearables, and ingestible and implantable sensors are increasingly used by individuals and clinicians to capture the health outcomes or behavioral and physiological characteristics of individuals. Time series classification (TSC) is very commonly used for modeling digital clinical measures. While deep learning models for TSC are very common and powerful, there exist some fundamental challenges. This review presents the non-deep learning models that are commonly used for time series classification in biomedical applications that can achieve high performance. Objective: We performed a systematic review to characterize the techniques that are used in time series classification of digital clinical measures throughout all the stages of data processing and model building. Methods: We conducted a literature search on PubMed, as well as the Institute of Electrical and Electronics Engineers (IEEE), Web of Science, and SCOPUS databases using a range of search terms to retrieve peer-reviewed articles that report on the academic research about digital clinical measures from a five-year period between June 2016 and June 2021. We identified and categorized the research studies based on the types of classification algorithms and sensor input types. Results: We found 452 papers in total from four different databases: PubMed, IEEE, Web of Science Database, and SCOPUS. After removing duplicates and irrelevant papers, 135 articles remained for detailed review and data extraction. Among these, engineered features using time series methods that were subsequently fed into widely used machine learning classifiers were the most commonly used technique, and also most frequently achieved the best performance metrics (77 out of 135 articles). Statistical modeling (24 out of 135 articles) algorithms were the second most common and also the second-best classification technique. Conclusions: In this review paper, summaries of the time series classification models and interpretation methods for biomedical applications are summarized and categorized. While high time series classification performance has been achieved in digital clinical, physiological, or biomedical measures, no standard benchmark datasets, modeling methods, or reporting methodology exist. There is no single widely used method for time series model development or feature interpretation, however many different methods have proven successful.

Recent Academic Research on Clinically Relevant Digital Measures: Systematic Review.

BACKGROUND: Digital clinical measures collected via various digital sensing technologies such as smartphones, smartwatches, wearables, ingestibles, and implantables are increasingly used by individuals and clinicians to capture health outcomes or behavioral and physiological characteristics of individuals. Although academia is taking an active role in evaluating digital sensing products, academic contributions to advancing the safe, effective, ethical, and equitable use of digital clinical measures are poorly characterized. OBJECTIVE: We performed a systematic review to characterize the nature of academic research on digital clinical measures and to compare and contrast the types of sensors used and the sources of funding support for specific subareas of this research. METHODS: We conducted a PubMed search using a range of search terms to retrieve peer-reviewed articles reporting US-led academic research on digital clinical measures between January 2019 and February 2021. We screened each publication against specific inclusion and exclusion criteria. We then identified and categorized research studies based on the types of academic research, sensors used, and funding sources. Finally, we compared and contrasted the funding support for these specific subareas of research and sensor types. RESULTS: The search retrieved 4240 articles of interest. Following the screening, 295 articles remained for data extraction and categorization. The top five research subareas included operations research (research analysis; n=225, 76%), analytical validation (n=173, 59%), usability and utility (data visualization; n=123, 42%), verification (n=93, 32%), and clinical validation (n=83, 28%). The three most underrepresented areas of research into digital clinical measures were ethics (n=0, 0%), security (n=1, 0.5%), and data rights and governance (n=1, 0.5%). Movement and activity trackers were the most commonly studied sensor type, and physiological (mechanical) sensors were the least frequently studied. We found that government agencies are providing the most funding for research on digital clinical measures (n=192, 65%), followed by independent foundations (n=109, 37%) and industries (n=56, 19%), with the remaining 12% (n=36) of these studies completely unfunded. CONCLUSIONS: Specific subareas of academic research related to digital clinical measures are not keeping pace with the rapid expansion and adoption of digital sensing products. An integrated and coordinated effort is required across academia, academic partners, and academic funders to establish the field of digital clinical measures as an evidence-based field worthy of our trust.

Wearable Patch-Based Estimation of Oxygen Uptake and Assessment of Clinical Status during Cardiopulmonary Exercise Testing in Patients With Heart Failure.

BACKGROUND: To estimate oxygen uptake (VO2) from cardiopulmonary exercise testing (CPX) using simultaneously recorded seismocardiogram (SCG) and electrocardiogram (ECG) signals captured with a small wearable patch. CPX is an important risk stratification tool for patients with heart failure (HF) owing to the prognostic value of the features derived from the gas exchange variables such as VO2. However, CPX requires specialized equipment, as well as trained professionals to conduct the study. METHODS AND RESULTS: We have conducted a total of 68 CPX tests on 59 patients with HF with reduced ejection fraction (31% women, mean age 55 ± 13 years, ejection fraction 0.27 ± 0.11, 79% stage C). The patients were fitted with a wearable sensing patch and underwent treadmill CPX. We divided the dataset into a training-testing set (n = 44) and a separate validation set (n = 24). We developed globalized (population) regression models to estimate VO2 from the SCG and ECG signals measured continuously with the patch. We further classified the patients as stage D or C using the SCG and ECG features to assess the ability to detect clinical state from the wearable patch measurements alone. We developed the regression and classification model with cross-validation on the training-testing set and validated the models on the validation set. The regression model to estimate VO2 from the wearable features yielded a moderate correlation (R2 of 0.64) with a root mean square error of 2.51 ± 1.12 mL · kg-1 · min-1 on the training-testing set, whereas R2 and root mean square error on the validation set were 0.76 and 2.28 ± 0.93 mL · kg-1 · min-1, respectively. Furthermore, the classification of clinical state yielded accuracy, sensitivity, specificity, and an area under the receiver operating characteristic curve values of 0.84, 0.91, 0.64, and 0.74, respectively, for the training-testing set, and 0.83, 0.86, 0.67, and 0.92, respectively, for the validation set. CONCLUSIONS: Wearable SCG and ECG can assess CPX VO2 and thereby classify clinical status for patients with HF. These methods may provide value in the risk stratification of patients with HF by tracking cardiopulmonary parameters and clinical status outside of specialized settings, potentially allowing for more frequent assessments to be performed during longitudinal monitoring and treatment.

Fabrication of Out-of-Plane High Channel Density Microelectrode Neural Array with 3D Recording and Stimulation Capabilities.

The Utah Electrode Array (UEA) and its different variants have become a gold standard in penetrating high channel count neural electrode for bi-directional neuroprostheses (simultaneous recording and stimulation). However, despite its usage in numerous applications, it has one major drawback of having only one active site per shaft, which is at the tip of the shaft. In this work, we are demonstrating a next-generation device, the Utah Multisite Electrode Array (UMEA), which is capable of having multiple sites around the shaft and also retaining the site at the tip. The UMEA can have up to 9 sites per shaft (hence can accommodate 900 active sites) while retaining the form factor of the conventional UEA with 100 sites. However, in this work and to show the proof of concept, the UMEA was fabricated with one active site at the tip and two around the shaft at different heights; thus, three active sites per shaft. The UMEA device is fabricated using a 3D shadow mask patterning technology, which is suitable for a batch fabrication process for these out-of-plane structures. The UMEA was characterized by in-vitro tests to showcase the electrochemical properties of the shaft sites for bi-directional neuroprostheses in contrast to the traditional tip sites of the standard UEA. The UMEA not only improves the channel density of conventional UEAs and hence can access a larger population of neurons, but also enhances the recording and stimulation capabilities from different layers of the human cortex without further increasing the risk of neuronal damage.

Demographic reporting in biosignal datasets: a comprehensive analysis of the PhysioNet open access database.

The PhysioNet open access database (PND) is one of the world's largest and most comprehensive repositories of biosignal data and is widely used by researchers to develop, train, and validate algorithms. To contextualise the results of such algorithms, understanding the underlying demographic distribution of the data is crucial-specifically, the race, ethnicity, sex or gender, and age of study participants. We sought to understand the underlying reporting patterns and characteristics of the demographic data of the datasets available on PND. Of the 181 unique datasets present in the PND as of July 6, 2023, 175 involved human participants, with less than 7% of studies reporting on all four of the key demographic variables. Furthermore, we found a higher rate of reporting sex or gender and age than race and ethnicity. In the studies that did include participant sex or gender, the samples were mostly male. Additionally, we found that most studies were done in North America, particularly in the USA. These imbalances and poor reporting of representation raise concerns regarding potential embedded biases in the algorithms that rely on these datasets. They also underscore the need for universal and comprehensive reporting practices to ensure equitable development and deployment of artificial intelligence and machine learning tools in medicine.

Assessment of ownership of smart devices and the acceptability of digital health data sharing.

Smart portable devices- smartphones and smartwatches- are rapidly being adopted by the general population, which has brought forward an opportunity to use the large volumes of physiological, behavioral, and activity data continuously being collected by these devices in naturalistic settings to perform research, monitor health, and track disease. While these data can serve to revolutionize health monitoring in research and clinical care, minimal research has been conducted to understand what motivates people to use these devices and their interest and comfort in sharing the data. In this study, we aimed to characterize the ownership and usage of smart devices among patients from an expansive academic health system in the southeastern US and understand their willingness to share data collected by the smart devices. We conducted an electronic survey of participants from an online patient advisory group around smart device ownership, usage, and data sharing. Out of the 3021 members of the online patient advisory group, 1368 (45%) responded to the survey, with 871 female (64%), 826 and 390 White (60%) and Black (29%) participants, respectively, and a slight majority (52%) age 58 and older. Most of the respondents (98%) owned a smartphone and the majority (59%) owned a wearable. In this population, people who identify as female, Hispanic, and Generation Z (age 18-25), and those completing higher education and having full-time employment, were most likely to own a wearable device compared to their demographic counterparts. 50% of smart device owners were willing to share and 32% would consider sharing their smart device data for research purposes. The type of activity data they are willing to share varies by gender, age, education, and employment. Findings from this study can be used to design both equitable and cost-effective digital health studies, leveraging personally-owned smartphones and wearables in representative populations, ultimately enabling the development of equitable digital health technologies.

Blood Pressure Variability in Clinical Practice: Past, Present and the Future.

Recent advances in wearable technology through convenient and cuffless systems will enable continuous, noninvasive monitoring of blood pressure (BP), heart rate, and heart rhythm on both longitudinal 24-hour measurement scales and high-frequency beat-to-beat BP variability and synchronous heart rate variability and changes in underlying heart rhythm. Clinically, BP variability is classified into 4 main types on the basis of the duration of monitoring time: very-short-term (beat to beat), short-term (within 24 hours), medium-term (within days), and long-term (over months and years). BP variability is a strong risk factor for cardiovascular diseases, chronic kidney disease, cognitive decline, and mental illness. The diagnostic and therapeutic value of measuring and controlling BP variability may offer critical targets in addition to lowering mean BP in hypertensive populations.

The 2023 wearable photoplethysmography roadmap.

Photoplethysmography is a key sensing technology which is used in wearable devices such as smartwatches and fitness trackers. Currently, photoplethysmography sensors are used to monitor physiological parameters including heart rate and heart rhythm, and to track activities like sleep and exercise. Yet, wearable photoplethysmography has potential to provide much more information on health and wellbeing, which could inform clinical decision making. This Roadmap outlines directions for research and development to realise the full potential of wearable photoplethysmography. Experts discuss key topics within the areas of sensor design, signal processing, clinical applications, and research directions. Their perspectives provide valuable guidance to researchers developing wearable photoplethysmography technology.

AI in medicine: Where are we now and where are we going?

Advancements in AI enable personalizing healthcare, for example by investigating disease origins at the genetic or molecular level, understanding intraindividual drug effects, and fusing multi-modal personal physiological, behavioral, laboratory, and clinical data to uncover new aspects of pathophysiology. Future efforts should address equity, fairness, explainability, and generalizability of AI models.

Estimation of Changes in Intracardiac Hemodynamics Using Wearable Seismocardiography and Machine Learning in Patients With Heart Failure: A Feasibility Study.

OBJECTIVE: Tracking changes in hemodynamic congestion and the consequent proactive readjustment of treatment has shown efficacy in reducing hospitalizations for patients with heart failure (HF). However, the cost-prohibitive nature of these invasive sensing systems precludes their usage in the large patient population affected by HF. The objective of this research is to estimate the changes in pulmonary artery mean pressure (PAM) and pulmonary capillary wedge pressure (PCWP) following vasodilator infusion during right heart catheterization (RHC), using changes in simultaneously recorded wearable seismocardiogram (SCG) signals captured with a small wearable patch. METHODS: A total of 20 patients with HF (20% women, median age 55 (interquartile range (IQR), 44-64) years, ejection fraction 24 (IQR, 16-43)) were fitted with a wearable sensing patch and underwent RHC with vasodilator challenge. We divided the dataset randomly into a training-testing set (n = 15) and a separate validation set (n = 5). We developed globalized (population) regression models to estimate changes in PAM and PCWP from the changes in simultaneously recorded SCG. RESULTS: The regression model estimated both pressures with good accuracies: root-mean-square-error (RMSE) of 2.5 mmHg and R2 of 0.83 for estimating changes in PAM, and RMSE of 1.9 mmHg and R2 of 0.93 for estimating changes in PCWP for the training-testing set, and RMSE of 2.7 mmHg and R2 of 0.81 for estimating changes in PAM, and RMSE of 2.9 mmHg and R2 of 0.95 for estimating changes in PCWP for the validation set respectively. CONCLUSION: Changes in wearable SCG signals may be used to track acute changes in intracardiac hemodynamics in patients with HF. SIGNIFICANCE: This method holds promise in tracking longitudinal changes in hemodynamic congestion in hemodynamically-guided remote home monitoring and treatment for patients with HF.

Demographic Imbalances Resulting From the Bring-Your-Own-Device Study Design.

Digital health technologies, such as smartphones and wearable devices, promise to revolutionize disease prevention, detection, and treatment. Recently, there has been a surge of digital health studies where data are collected through a bring-your-own-device (BYOD) approach, in which participants who already own a specific technology may voluntarily sign up for the study and provide their digital health data. BYOD study design accelerates the collection of data from a larger number of participants than cohort design; this is possible because researchers are not limited in the study population size based on the number of devices afforded by their budget or the number of people familiar with the technology. However, the BYOD study design may not support the collection of data from a representative random sample of the target population where digital health technologies are intended to be deployed. This may result in biased study results and biased downstream technology development, as has occurred in other fields. In this viewpoint paper, we describe demographic imbalances discovered in existing BYOD studies, including our own, and we propose the Demographic Improvement Guideline to address these imbalances.

A method for intelligent allocation of diagnostic testing by leveraging data from commercial wearable devices: a case study on COVID-19.

Mass surveillance testing can help control outbreaks of infectious diseases such as COVID-19. However, diagnostic test shortages are prevalent globally and continue to occur in the US with the onset of new COVID-19 variants and emerging diseases like monkeypox, demonstrating an unprecedented need for improving our current methods for mass surveillance testing. By targeting surveillance testing toward individuals who are most likely to be infected and, thus, increasing the testing positivity rate (i.e., percent positive in the surveillance group), fewer tests are needed to capture the same number of positive cases. Here, we developed an Intelligent Testing Allocation (ITA) method by leveraging data from the CovIdentify study (6765 participants) and the MyPHD study (8580 participants), including smartwatch data from 1265 individuals of whom 126 tested positive for COVID-19. Our rigorous model and parameter search uncovered the optimal time periods and aggregate metrics for monitoring continuous digital biomarkers to increase the positivity rate of COVID-19 diagnostic testing. We found that resting heart rate (RHR) features distinguished between COVID-19-positive and -negative cases earlier in the course of the infection than steps features, as early as 10 and 5 days prior to the diagnostic test, respectively. We also found that including steps features increased the area under the receiver operating characteristic curve (AUC-ROC) by 7-11% when compared with RHR features alone, while including RHR features improved the AUC of the ITA model's precision-recall curve (AUC-PR) by 38-50% when compared with steps features alone. The best AUC-ROC (0.73 ± 0.14 and 0.77 on the cross-validated training set and independent test set, respectively) and AUC-PR (0.55 ± 0.21 and 0.24) were achieved by using data from a single device type (Fitbit) with high-resolution (minute-level) data. Finally, we show that ITA generates up to a 6.5-fold increase in the positivity rate in the cross-validated training set and up to a 4.5-fold increase in the positivity rate in the independent test set, including both symptomatic and asymptomatic (up to 27%) individuals. Our findings suggest that, if deployed on a large scale and without needing self-reported symptoms, the ITA method could improve the allocation of diagnostic testing resources and reduce the burden of test shortages.

Taking the time for our bodies: How wearables can be used to assess circadian physiology.

Consumer wearables, such as smart watches, are a promising tool for monitoring circadian health in "real world" settings. Bowman et al. demonstrate that circadian signals can be accurately captured through heart rate data obtained from wearables, opening up new possibilities for population-level studies on heart rate and circadian rhythm.

The Delineation of Fiducial Points for Non-Contact Radar Seismocardiogram Signals Without Concurrent ECG.

OBJECTIVE: Non-contact sensing of seismocardiogram (SCG) signals through a microwave Doppler radar is promising for biomedical applications. However, the delineation of fiducial points for radar SCG still relies on concurrent ECG which requires a contact sensor and limits the complete non-contact detection of SCG. METHODS: Instead of ECG, a new reference signal, the radar displacement signal of heartbeat (RDH), was derived through the complex Fourier transform and the band pass filtering of the radar signal. The RDH signal was used to locate each cardiac cycle and mask the systolic profile, which was further used to detect an important fiducial point, aortic valve opening (AO). The beat-to-beat interval was estimated from AO-AO interval and compared with the gold standard, ECG R-to-R interval. RESULTS: For the 22 subjects in the study, the evaluation of the AOs detected by RDH (AORDH) shows the average detection ratio can reach 90%, indicating a high ratio of the AORDH that are exactly the same as AO detected using the ECG R-wave (AOECG). Additionally, the left ventricular ejection time (LVET) values estimated from the ensemble averaged radar waveform through AORDH segmentation are within 2 ms of those through AOECG segmentation, for all the detected subjects. Further analysis demonstrates that the beat-to-beat intervals calculated from AORDH have an average root-mean-square-deviation (RMSD) of 53.73 ms when compared with ECG R-to-R intervals, and have an average RMSD of 23.47 ms after removing the beats in which AO cannot be identified. CONCLUSIONS: Radar signal RDH can be used as a reference signal to delineate fiducial points for non-contact radar SCG signals. SIGNIFICANCE: This study can be applied to develop complete non-contact sensing of SCG and monitoring of vital signs, where contact-based SCG is not feasible.

Estimation of Instantaneous Oxygen Uptake During Exercise and Daily Activities Using a Wearable Cardio-Electromechanical and Environmental Sensor.

OBJECTIVE: To estimate instantaneous oxygen uptake VO2 with a small, low-cost wearable sensor during exercise and daily activities in order to enable monitoring of energy expenditure (EE) in uncontrolled settings. We aim to do so using a combination of seismocardiogram (SCG), electrocardiogram (ECG) and atmospheric pressure (AP) signals obtained from a minimally obtrusive wearable device. METHODS: In this study, subjects performed a treadmill protocol in a controlled environment and an outside walking protocol in an uncontrolled environment. During testing, the COSMED K5 metabolic system collected gold standard breath-by-breath (BxB) data and a custom-built wearable patch placed on the mid-sternum collected SCG, ECG and AP signals. We extracted features from these signals to estimate the BxB VO2 data obtained from the COSMED system. RESULTS: In estimating instantaneous VO2, we achieved our best results on the treadmill protocol using a combination of SCG (frequency) and AP features (RMSE of 3.68 ± 0.98 ml/kg/min and R2 of 0.77). For the outside protocol, we achieved our best results using a combination of SCG (frequency), ECG and AP features (RMSE of 4.3 ± 1.47 ml/kg/min and R2 of 0.64). In estimating VO2 consumed over one minute intervals during the protocols, our median percentage error was 15.8[Formula: see text] for the treadmill protocol and 20.5[Formula: see text] for the outside protocol. CONCLUSION: SCG, ECG and AP signals from a small wearable patch can enable accurate estimation of instantaneous VO2 in both controlled and uncontrolled settings. SCG signals capturing variation in cardio-mechanical processes, AP signals, and state of the art machine learning models contribute significantly to the accurate estimation of instantaneous VO2. SIGNIFICANCE: Accurate estimation of VO2 with a low cost, minimally obtrusive wearable patch can enable the monitoring of VO2 and EE in everyday settings and make the many applications of these measurements more accessible to the general public.

Use of Ballistocardiography to Monitor Cardiovascular Hemodynamics in Preeclampsia.

Objective: Pregnancy requires a complex physiological adaptation of the maternal cardiovascular system, which is disrupted in women with pregnancies complicated by preeclampsia, putting them at higher risk of future cardiovascular events. The measurement of body movements in response to cardiac ejection via ballistocardiogram (BCG) can be used to assess cardiovascular hemodynamics noninvasively in women with preeclampsia. Methods: Using a previously validated, modified weighing scale for assessment of cardiovascular hemodynamics through measurement of BCG and electrocardiogram (ECG) signals, we collected serial measurements throughout pregnancy and postpartum and analyzed data in 30 women with preeclampsia and 23 normotensive controls. Using BCG and ECG signals, we extracted measures of cardiac output, J-wave amplitude × heart rate (J-amp × HR). Mixed-effect models with repeated measures were used to compare J-amp × HRs between groups at different time points in pregnancy and postpartum. Results: In normotensive controls, the J-amp × HR was significantly lower early postpartum (E-PP) compared with the second trimester (T2; p = 0.016) and third trimester (T3; p = 0.001). Women with preeclampsia had a significantly lower J-amp × HR compared with normotensive controls during the first trimester (T1; p = 0.026). In the preeclampsia group, there was a trend toward an increase in J-amp × HR from T1 to T2 and then a drop in J-amp × HR at T3 and further drop at E-PP. Conclusions: We observe cardiac hemodynamic changes consistent with those reported using well-validated tools. In pregnancies complicated by preeclampsia, the maximal force of contraction is lower, suggesting lower cardiac output and a trend in hemodynamics consistent with the hyperdynamic disease model of preeclampsia.

A Globalized Model for Mapping Wearable Seismocardiogram Signals to Whole-Body Ballistocardiogram Signals Based on Deep Learning.

The ballistocardiography (BCG) signal is a measurement of the vibrations of the center of mass of the body due to the cardiac cycle and can be used for noninvasive hemodynamic monitoring. The seismocardiography (SCG) signals measure the local vibrations of the chest wall due to the cardiac cycle. While BCG is a more well-known modality, it requires the use of a modified bathroom scale or a force plate and cannot be measured in a wearable setting, whereas SCG signals can be measured using wearable accelerometers placed on the sternum. In this paper, we explore the idea of finding a mapping between zero mean and unit l2-norm SCG and BCG signal segments such that, the BCG signal can be acquired using wearable accelerometers (without retaining amplitude information). We use neural networks to find such a mapping and make use of the recently introduced UNet architecture. We trained our models on 26 healthy subjects and tested them on ten subjects. Our results show that we can estimate the aforementioned segments of the BCG signal with a median Pearson correlation coefficient of 0.71 and a median absolute deviation (MAD) of 0.17. Furthermore, our model can estimate the R-I, R-J and R-K timing intervals with median absolute errors (and MAD) of 10.00 (8.90), 6.00 (5.93), and 8.00 (5.93), respectively. We show that using all three axis of the SCG accelerometer produces the best results, whereas the head-to-foot SCG signal produces the best results when a single SCG axis is used.

A Unified Framework for Quality Indexing and Classification of Seismocardiogram Signals.

The seismocardiogram (SCG) is a noninvasively-obtained cardiovascular bio-signal that has gained traction in recent years, however is limited by its susceptibility to noise and motion artifacts. Because of this, signal quality must be assured before data are used to inform clinical care. Common methods of signal quality assurance include signal classification or assignment of a numerical quality index. Such tasks are difficult with SCG because there is no accepted standard for signal morphology. In this paper, we propose a unified method of quality indexing and classification that uses multi-subject-based methods to overcome this challenge. Dynamic-time feature matching is introduced as a novel method of obtaining the distance between a signal and reference template, with this metric, the signal quality index (SQI) is defined as a function of the inverse distance between the SCG and a large set of template signals. We demonstrate that this method is able to stratify SCG signals on held-out subjects based on their level of motion-artifact corruption. This method is extended, using the SQI as a feature for classification by ensembled quadratic discriminant analysis. Classification is validated by demonstrating, for the first time, both detection and localization of SCG sensor misplacement, achieving an F1 score of 0.83 on held-out subjects. This paper may provide a necessary step toward automating the analysis of SCG signals, addressing many of the key limitations and concerns precluding the method from being widely used in clinical and physiological sensing applications.